Your browser doesn't support javascript.
loading
Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding, N S; McDonald, J A K; Perdones-Montero, A; Rees, Douglas N; Adegbola, S O; Misra, R; Hendy, P; Penez, L; Marchesi, J R; Holmes, E; Sarafian, M H; Hart, A L.
Afiliação
  • Ding NS; St Vincent's Hospital, Inflammatory Bowel Disease, Melbourne, VIC, Australia.
  • McDonald JAK; St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK.
  • Perdones-Montero A; Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Rees DN; Division of Digestive Diseases, Department of Surgery and Cancer, St Mary's Hospital, Imperial College London, London, UK.
  • Adegbola SO; Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Misra R; Division of Digestive Diseases, Department of Surgery and Cancer, St Mary's Hospital, Imperial College London, London, UK.
  • Hendy P; St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK.
  • Penez L; Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Marchesi JR; St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK.
  • Holmes E; Division of Computational Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Sarafian MH; St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK.
  • Hart AL; St Mark's Hospital, Inflammatory Bowel Disease Unit, London, UK.
J Crohns Colitis ; 14(8): 1090-1102, 2020 Sep 07.
Article em En | MEDLINE | ID: mdl-32119090
ABSTRACT
BACKGROUND AND

AIMS:

Anti-tumour necrosis factor [anti-TNF] therapy is indicated for treatment of moderate to severe inflammatory bowel disease [IBD], but has a primary non-response rate of around 30%. We aim to use metabonomic and metataxonomic profiling to identify predictive biomarkers of anti-TNF response in Crohn's disease.

METHODS:

Patients with luminal Crohn's disease, commencing anti-TNF therapy, were recruited with urine, faeces, and serum samples being collected at baseline and 3-monthly. Primary response was defined according to a combination of clinical and objective markers of inflammation. Samples were measured using three UPLC-MS assays lipid, bile acid, and Hydrophillic Interaction Liquid Chromatography [HILIC] profiling with 16S rRNA gene sequencing of faeces.

RESULTS:

Samples were collected from 76 Crohn's disease patients who were anti-TNF naïve and from 13 healthy controls. There were 11 responders, 37 non-responders, and 28 partial responders in anti-TNF-treated Crohn's patients. Histidine and cysteine were identified as biomarkers of response from polar metabolite profiling [HILIC] of serum and urine. Lipid profiling of serum and faeces found phosphocholines, ceramides, sphingomyelins, and triglycerides, and bile acid profiling identified primary bile acids to be associated with non-response to anti-TNF therapy, with higher levels of phase 2 conjugates in non-responders. Receiver operating curves for treatment response demonstrated 0.94 +/ -0.10 [faecal lipid], 0.81 +/- 0.17 [faecal bile acid], and 0.74 +/- 0.15 [serum bile acid] predictive ability for anti-TNF response in Crohn's disease.

CONCLUSIONS:

This prospective, longitudinal cohort study of metabonomic and 16S rRNA gene sequencing analysis demonstrates that a range of metabolic biomarkers involving lipid, bile acid, and amino acid pathways may contribute to prediction of response to anti-TNF therapy in Crohn's disease. PODCAST This article has an associated podcast which can be accessed at https//academic.oup.com/ecco-jcc/pages/podcast.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / RNA Ribossômico 16S / Doença de Crohn / Cisteína / Metabolismo dos Lipídeos / Adalimumab / Infliximab / Histidina / Inflamação Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: J Crohns Colitis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / RNA Ribossômico 16S / Doença de Crohn / Cisteína / Metabolismo dos Lipídeos / Adalimumab / Infliximab / Histidina / Inflamação Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: J Crohns Colitis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália